Name (Synonyms) | Correlation | |
---|---|---|
drug2922 | non-RAS blocking antihypertensives Wiki | 1.00 |
drug518 | Candesartan Wiki | 1.00 |
drug338 | Best standard of care Wiki | 1.00 |
drug2516 | Thromboprophylaxis Wiki | 1.00 |
drug2952 | placebo for clazakizumab Wiki | 1.00 |
drug566 | Chloroquine or Hydroxychloroquine Wiki | 0.58 |
drug2105 | Rivaroxaban Wiki | 0.58 |
drug1368 | Lopinavir/Ritonavir Wiki | 0.58 |
drug1852 | Placebo oral capsule Wiki | 0.58 |
drug576 | Clazakizumab Wiki | 0.45 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
In this study we propose to treat 560 patients with ramipril or placebo for 14 days. After an initial evaluation for COVID-19 status, medical history, and symptom assessment, patients will receive either 2.5 mg/day of ramipril or placebo. Patients' symptoms and study endpoints will be monitored at regular intervals. After 14 days, patients will undergo a laboratory assessment and an end-of-treatment follow-up visit at day 28. The primary endpoints of successful therapy will be improved survival, reductions in ICU admissions, and/or reductions in use of mechanical ventilator support.
Description: The major primary outcome to be evaluated is improving a composite outcome of mortality or need for ICU admission or ventilator use within a 14-day window.
Measure: Composite of mortality or need for ICU admission or ventilator use Time: 14 days